Issue link: https://www.e-digitaleditions.com/i/1138630
6 July 2019 Tablets & Capsules research Growing number of US allergists prescribe tablets over shots ARLINGTON HEIGHTS, IL— In the last five years, the number of US allergists prescribing sublin- gual immunotherapy (SLIT) tab- lets rather than the more traditional allergy shots has grown, according to a study published by the Amer- ican College of Allergy, Asthma, and Immunology (ACAAI) Immu- notherapy and Diagnostics com- mittee. The organization sent out an electronic survey to US and international allergists who are also ACAAI members and compared the results with previous surveys con- ducted and published in 2007 and 2011. Of the 305 respondents, 268 (87.9 percent) practiced in the US and of those 268 US allergists, 197 (73.5 percent) reported prescrib- ing SLIT to patients, showing a sig- nificant increase compared to the surveys in 2007 (5.9 percent) and 2011 (11.4 percent). This growing use of SLIT prescriptions may have been driven by four recent FDA-ap- proved SLIT options. markets Latin American pharmaceutical excipients market to reach $579 billion by 2024 NORTHBROOK, IL—The Latin American pharmaceutical excip- ients market is projected to reach $579 billion by 2024, growing at a compound annual rate of 7.5 per- cent, according to a report by Mar- kets and Markets. Elements driving growth in this region include the growing pharmaceutical industry in Latin American countries such as Brazil, Mexico, and Argentina; multinational corporations' increas- ing focus on investing in the Latin A m e r i c a n p h a r m a c e u t i c a l a n d healthcare sectors; a rapidly grow- ing aging population and the subse- quent increase in the prevalence of related diseases; and local and gov- ernment funding for R&D activities. The report identifies DowDuPont, Roquette, Ashland, BASF, and Kerry as major players in the Latin Ameri- can pharmaceutical excipient market. Growing demand for SODFs to drive nutraceutical excipient market growth VALLEY COTTAGE, NY—The increasing prevalence of lifestyle- related diseases, leading to mount- ing sales of dietary supplements and functional foods and beverages, is expected to drive growth in the global nutraceutical excipients mar- ket, according to a report by Future Market Insights. The report fore- casts the market to grow at a com- pound annual rate of 7.1 percent through 2029. Binders, fillers, and diluents are expected to remain the most preferred product types for nutraceutical excipients due to the growing demand for solid oral dos- Budenheim offers a comprehensive range of superior phosphate products ... covering liquid and solid dosage forms and a wide range of functionalities for pharmaceutical companies. All DI-CAFOS ® and TRI-CAFOS ® grades for direct compression offer several advantages which include excellent flow properties, high tablet hardness and high content uniformity which are essential for high speed tablet manufacturing. ... and extensive global services, in- cluding technical and regulatory support completes the offer to our customers and has made Budenheim a leading player in this segment. Our Tabletting Competence Center enables us to run trials under real production conditions, helps us to understand the require- ments of the market and to develop customized solutions for you. TRI - CAFOS ® Superior excipients meeting your formulation challenges DI - CAFOS ® Budenheim USA, Inc. | 855 Grandview Avenue Suite 120 | Columbus, Ohio 43215 Phone +1 (614) 869 1600 | pharma@budenheim.com | www.budenheim.com